Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects.
OBJECTIVE
Our objective was to evaluate preferences associated with grade I/II and grade III/IV chemotherapy side effects among breast cancer patients receiving chemotherapy. We also assessed trade-offs that patients are willing to make between treatment side effects and the route and schedule of treatment administration.


METHODS
In this cross-sectional study, patients receiving chemotherapy for breast cancer completed a one-time Web survey. Conjoint analysis was used to elicit preferences for 17 grade I/II and III/IV side effects associated with available chemotherapies and regimens. In the analysis, the risk of each side effect was increased by 5%, holding all others constant, and the respective impact on patient preferences was identified.


RESULTS
A total of 102 women participated (mean age 54 ± 11). Among the grade I/II side effects, a 5% reduction in the risk of sensory neuropathy, nausea, and motor neuropathy had the highest impact on preferences. Among grade III/IV side effects, motor neuropathy, nausea/vomiting, and myalgia made the most difference. An oral twice-daily regimen was most preferred; however, patients were willing to receive an intravenous regimen relative to oral to avoid an increased risk of 5% in the majority of side effects. Avoiding an increased chance of grade III/IV motor neuropathy was associated with willingness to tolerate one of the least preferred administration schedules.


CONCLUSIONS
This study identified relative preferences among both mild/moderate to severe side effects from the patient perspective. Patients appear to be willing to make trade-offs between side effects and different regimens. These findings may help to inform medical decision-making processes.
Outcomes Research Strategies in Health, Washington, D.C., USA; Oxford Outcomes, an ICON plc Company, Bethesda, Maryland, USA; Division of Medical Oncology, Ottawa Hospital Cancer Centre, and Department of Medicine, University of Ottawa, Ottawa, Canada; Division of Medical Oncology, Royal Victoria Hospital, McGill University, Montreal, Canada.
Kathleen
K
Beusterien
Jessica
J
Grinspan
Iryna
I
Kuchuk
Sasha
S
Mazzarello
Susan
S
Dent
Stan
S
Gertler
Nathaniel
N
Bouganim
Lisa
L
Vandermeer
Mark
M
Clemons
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000523:psychology*; D003430:Cross-Sectional Studies; D003625:Data Collection; D005260:Female; D006801:Humans; D020407:Internet; D008875:Middle Aged; D060787:Neoplasm Grading; D057240:Patient Preference / Q000706:statistics & numerical data*
Breast cancer; Conjoint; Preferences; Side effects; Tradeoffs